

IFW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/596,997
	Filing Date	July 5, 2006
	First Named Inventor	Stephen Gillies
	Art Unit	1645
	Examiner Name	Not yet assigned
Total Number of Pages in This Submission	Attorney Docket Number	ANTBH/P31763US

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 18 pages PTO Form 1449, 185 references, return receipt postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Pabst Patent Group LLP		
Signature			
Printed name	Charles Vorndran, Ph.D.		
Date	October 24, 2007	Reg. No.	45,315

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name	Peggy McKinney	Date	October 24, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/17 (05-07)

Approved for use through 05/31/2007. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number

Effective on 12/08/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL

For FY 2007

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)

Complete if Known

Application Number	10/596,997
Filing Date	July 5, 2006
First Named Inventor	Stephen Gillies
Examiner Name	Not Yet Assigned
Art Unit	1645
Attorney Docket No.	ANTBH/P31763US

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____☒ Deposit Account Deposit Account Number: 50-3129 Deposit Account Name: Pabst Patent Group LLP

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☐ Charge fee(s) indicated below☐ Charge fee(s) indicated below, **except for the filing fee**☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17☒ Credit any overpayments**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**FEE CALCULATION****1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEES**Fee Description**

Each claim over 20 (including Reissues)

Fee (\$)	Small Entity Fee (\$)
50	25
200	100
360	180

Each independent claim over 3 (including Reissues)

Multiple dependent claims

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
--------------	--------------	----------	---------------

 $\text{HP} = \text{highest number of total claims paid for, if greater than 20.}$

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
---------------	--------------	----------	---------------

 $\text{HP} = \text{highest number of independent claims paid for, if greater than 3.}$ **3. APPLICATION SIZE FEE**

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
--------------	--------------	--	----------	---------------

 $\text{HP} - 100 = \text{ } / 50 = \text{ } \text{ (round up to a whole number) } \times \text{ } = \text{ }$ **4. OTHER FEE(S)**

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): _____

Fees Paid (\$)**SUBMITTED BY**

Signature		Registration No. (Attorney/Agent) 45,315	Telephone 404-879-2153
Name (Print/Type)	Charles Vorndran		Date October 24, 2007

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Stephen Gillies, Kin-Ming Lo, Yan Lan and Rakesh Verma

Serial No.: 10/596,997

Art Unit: 1645

I.A. Filed: July 5, 2006

Examiner: Not Yet Assigned

For: *COMPOUNDS FOR TARGETING*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including eighteen (18) pages of Form PTO-1449, and copies of one hundred eighty-five (185) documents cited therein. Pursuant to the waiver in the notice entitled "Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications Filed After June 30, 2003" published on August 5, 2003 in 1273 OG 55, copies of U.S. Patents and Published Applications are not enclosed. Copies will be provided upon request, however.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1329.

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
4,440,859	04-03-1984	Rutter, et al.	435/91.41
4,469,797	09-04-1984	Albarella	436/536
4,530,901	07-23-1985	Weissmann	435/69.51
4,582,800	04-15-1986	Crowl	435/69.51
4,677,063	06-30-1987	Mark, et al.	435/69.5
4,678,751	07-07-1987	Goeddel	435/252.3
4,704,362	11-03-1987	Itakura, et al.	435/252.3
4,710,463	12-01-1987	Murray	435/69.3
4,757,006	07-12-1988	Toole, Jr., et al.	435/69.6
4,766,075	08-23-1988	Goeddel, et al.	435/369
4,810,648	03-07-1989	Stalker	435/191
5,019,368	05-28-1991	Epstein, et al.	424/1.49
5,073,627	12-17-1991	Curtis, et al.	530/351
5,199,942	04-06-1993	Gillies	604/4.01
5,349,053	09-20-1994	Landolfi	530/351
5,457,038	10-10-1995	Trinchieri, et al.	435/69.52
5,480,981	01-02-1996	Goodwin, et al.	536/23.5
5,609,846	03-11-1997	Goldenberg	424/1.41
5,614,184	03-25-1997	Sytowski, et al.	424/85.1
5,650,150	07-22-1997	Gillies	424/134.1
5,650,492	07-22-1997	Gately, et al.	530/351
5,709,859	01-30-1998	Aruffo, et al.	424/134.1
5,728,552	03-17-1998	Fujisawa, et al.	435/69.5
5,858,347	01-12-1999	Bauer, et al.	424/85.2
5,891,680	04-06-1999	Lieschke, et al.	435/69.52
5,922,685	07-13-1999	Rakhmilevich, et al.	514/44
5,994,104	11-30-1999	Anderson, et al.	435/69.52
6,086,875	07-11-2000	Blumberg, et al.	424/134.1
6,169,070	01-02-2001	Chen, et al.	514/2
6,335,176	01-01-2002	Inglese, et al.	435/7.72
6,444,792	09-03-2002	Gray, et al.	530/387.3
6,485,726	11-26-2002	Blumberg, et al.	424/178.1
6,500,641	12-31-2002	Chen, et al.	435/69.1
6,551,592	04-22-2003	Lindhofer, et al.	424/136.1
6,620,413	09-16-2003	Sauvage, et al.	424/178.1
6,750,329	06-15-2004	Rosenblum, et al.	530/391.7

U.S. Patent Applications

<u>Number</u>	<u>Publication Date</u>	<u>Inventor</u>	<u>Class/Subclass</u>
2001/0053539	12-20-2001	Lauffer, et al.	435/69.7
2002/0142374	10-03-2002	Gallo, et al.	435/69.1
2002/0192222	12-19-2002	Blumberg, et al.	424/178.1
2003/0012789	01-16-2003	Blumberg, et al.	424/145.1
2004/0013640	01-22-2004	Zardi, et al.	424/85.1

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
0 239 400	09-30-1987	Gregory Paul Winter	EP
0 251 744	01-07-1988	Delta Biotechnology, Ltd.	EP
0 258 067	03-02-1988	Delta Biotechnology, Ltd.	EP
0 344 134	11-29-1989	Ist. Naz. Ric. Sul. Cancro.	EP
0 350 230	01-10-1990	Res. Dev. Foundation	EP
0 375 562	06-27-1990	Oncogen	EP
0 396 387	11-07-1990	Res. Dev. Foundation	EP
0 433 827	06-26-1991	Hoffman La Roche	EP
0 706 799	04-17-1996	Merck Patent GmbH	EP
0 790 309	08-20-1997	Hoffman La Roche	EP
WO 88/00052	01-14-1988	Dartmouth College	PCT
WO 89/02922	04-06-1989	Genentech, Inc.	PCT
WO 90/01063	02-08-1990	Delta Biotechnology, Ltd.	PCT
WO 91/00360	01-10-1991	Medarex, Inc.	PCT
WO 91/14438	10-03-1991	University of Columbia	PCT
WO 95/21258	08-10-1995	U.S. Government	PCT
WO 95/31483	11-23-1995	Eclagen, Ltd.	PCT
WO 96/04388	02-15-1996	Smithkline Beecham, PLC	PCT
WO 96/18412	06-20-1996	Beth Israel Hospital	PCT
WO 96/40792	12-19-1996	Novonordisk AS	PCT
WO 97/00319	01-03-1997	Smithkline Beecham, PLC	PCT
WO 97/20062	06-05-1997	University of Massachusetts	PCT
WO 97/24440	07-10-1997	Genentech, Inc.	PCT
WO 97/33617	09-18-1997	Protein Design Labs, Inc.	PCT
WO 97/33619	09-18-1997	QLT Phototherapeutics, Inc.	PCT
WO 97/43316	11-20-1997	Beth Israel Hospital	PCT
WO 98/00127	01-08-1998	Univ. Bar Ilan	PCT
WO 98/28427	07-02-1998	Amgen, Inc.	PCT
WO 98/30706	07-16-1998	Alliance Pharma	PCT
WO 98/46257	10-22-1998	Amgen, Inc.	PCT
WO 99/02709	01-21-1999	Beth Israel Hospital	PCT

WO 99/29732	06-17-1999	Lexigen Pharm Corp	PCT
WO 99/43713	09-02-1999	Lexigen Pharm Corp	PCT
WO 99/52562	10-21-1999	Lexigen Pharm Corp	PCT
WO 99/53958	10-28-1999	Lexigen Pharm Corp	PCT
WO 00/11033	03-02-2000	Lexigen Pharm Corp	PCT
WO 00/40615	07-13-2000	Lexigen Pharm Corp	PCT
WO 00/69913	11-23-2000	Lexigen Pharm Corp	PCT
WO 01/07081	02-01-2001	Lexigen Pharm Corp	PCT
WO 01/36489	05-25-2001	Merck Patent GmbH	PCT
WO 01/58957	08-16-2001	Lexigen Pharm Corp	PCT
WO 02/02143	01-10-2002	Lexigen Pharm Corp	PCT
WO 02/066514	08-29-2002	Lexigen Pharm Corp	PCT
WO 02/072605	09-19-2002	Lexigen Pharm Corp	PCT
WO 02/090566	11-14-2002	Lexigen Pharm Corp	PCT
WO 03/015697	02-27-2003	Univ. Southern California	PCT
WO 03/048334	06-12-2003	EMD Lexigen Res. CT Corp.	PCT
WO 03/076469	09-18-2003	Philogen S R L; Schering AG	PCT
WO 03/077834	09-25-2003	Brigham and Women's Hospital	PCT
WO 03/093478	11-13-2003	Molmed SPA	PCT

Publications

AFONSO, et al., "The adjuvant effect of interleukin-12 in a vaccine against *Leishmania major*", *Science*, 263(5144):235-7 (1994).

ANSELL, et al., "Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma", *Blood*, 99(1):67-74 (2002).

BARBULESCU, et al., "IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes", *J. Immunol.*, 160(8):3642-7 (1998).

BEGGS, "Transformation of yeast by a replicating hybrid plasmid", *Nature*, 275(5676):104-9 (1978).

BERENT, et al., "Comparison of oligonucleotide and long DNA fragments as probes in DNA and RNA dot, southern, northern, colony and plaque hybridizations", *Biotechniques*, 3:208-220 (1985).

BETTER, et al., "*Escherichia coli* secretion of an active chimeric antibody fragment", *Science*, 240(4855):1041-3 (1988).

BIRD, et al., "Single-chain antigen-binding proteins", *Science*, 242(4877):423-6 (1988).

BITONTI, et al., "Transepithelial absorption of an erythropoietin-Fc fusion protein after delivery to the central airways", *Respiratory Drug Delivery*, 8:308-312 (2002).

BOSHART, et al., "A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus", *Cell*, 41(2):521-30 (1985).

CARNEMOLLA, et al., "A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors", *J. Cell Biol.*, 108(3):1139-1148 (1989).

CARNEMOLLA, et al., "The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence", *J. Biol. Chem.*, 267(34):24689-92 (1992).

CHAN, "Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers", *J. Exp. Med.*, 173(4):869-79 (1991).

CHEN, et al., "Eradication of murine bladder carcinoma by intratumor injection of a bicistronic adenoviral vector carrying cDNAs for the IL-12 heterodimer and its inhibition by the IL-12 p40 subunit homodimer", *J. Immunol.*, 159(1):351-9 (1997).

COHEN, et al., "Nonchromosomal antibiotic resistance in bacteria: genetic transformation of *Escherichia coli* by R-factor DNA", *Proc. Natl. Acad. Sci. U.S.A.*, 69(8):2110-4 (1972).

COLOMBO, et al., "Amount of interleukin 12 available at the tumor site is critical for tumor regression", *Cancer Res.*, 56(11):2531-4 (1996).

D'ANDREA, et al., "Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells", *J. Exp. Med.*, 176(5):1387-98 (1992).

DESAI, et al., "IL-12 receptor. II. Distribution and regulation of receptor expression", *J. Immunol.*, 148(10):3125-32 (1992).

DICKERSON, et al., Proceedings of the American Association for Cancer Research Annual Meeting No. 41, page 798, abstract no. 5074 (2000).

DORAN, et al., "Expression of ED-B fibronectin in renal carcinoma and metastatic melanoma and targeted therapy with AS1409, a potent immunocytokine", Abstract presentation 5th Int. Congress on Targeted Therapies in Cancer, NY (2006).

EMTAGE, et al., "Generating potent Th1/Tc1 T cell adoptive immunotherapy doses using human IL-12: Harnessing the immunomodulatory potential of IL-12 without the in vivo-associated toxicity", *J. Immunother.*, 26(2):97-106 (2003).

FFRENCH-CONSTANT, et al., "Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat", *J. Cell Biol.*, 109(2):903-14 (1989).

GATELY, et al., "The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses", *Annu. Rev. Immunol.*, 16:495-521 (1998).

GILLESSEN, et al., "Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist", *Eur. J. Immunol.*, 25(1):200-6 (1995).

GILLIES, et al., "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases", *J. Immunol.*, 160(12):6195-203 (1998).

GILLIES, et al., "Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis", *Clin. Cancer Res.*, 8(1):210-6 (2002).

GOLLOB, et al., "Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response", *Clin. Cancer Res.*, 6(5):1678-92 (2000).

GUBLER and PRESKY, "Molecular biology of interleukin-12 receptors", *Ann. N.Y. Acad. Sci.*, 795:36-40 (1996).

HALIN, et al., "Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature", *Nat. Biotechnol.*, 20(3):264-9 (2002).

HALIN, "Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha", *Cancer Res.*, 63(12):3202-10 (2003).

HASHIMOTO, et al., "Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively", *J. Immunol.*, 163(2):583-9 (1999).

HEINZEL, et al., "In vivo production and function of IL-12 p40 homodimers", *J. Immunol.*, 158(9):4381-8 (1997).

HEINZERLING, et al., "Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice", *Exp. Dermatol.*, 11(3):232-40 (2002).

HOOGENBOOM, et al, "Construction and expression of antibody-tumor necrosis factor fusion proteins", *Mol. Immunol.*, 28(9):1027-37 (1991).

HOOGENBOOM, et al., "Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule", *Biochim. Biophys. Acta.*, 1096(4):345-54 (1991).

HUANG, et al., "Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature", *Science*, 275(5299):547-50 (1997).

HUSTON, et al., "Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in *Escherichia coli*", *Proc. Natl. Acad. Sci. U.S.A.*, 85(16):5879-83 (1988).

IWASAKI, et al., "A critical role for IL-12 in CCR5 induction on T cell receptor-triggered mouse CD4(+) and CD8(+) T cells", *Eur. J. Immunol.*, 31(8):2411-20 (2001).

JONES, et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse", *Nature*, 321(6069):522-5 (1986).

JONES, et al., "The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection", *J. Interferon Cytokine Res.*, 24(9):560-72 (2004).

JONES, et al., "Production of an IgG1-IL12 fusion protein", presentation at *Optimizing Cell Culture Development* (2006).

KANG, et al., "Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study", *Hum. Gene Ther.*, 12(6):671-84 (2001).

KIM, "An ovalbumin-IL-12 fusion protein is more effective than ovalbumin plus free recombinant IL-12 in inducing a T helper cell type 1-dominated immune response and inhibiting antigen-specific IgE production", *J. Immunol.*, 158(9):4137-44 (1997).

KING, et al., "Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients", *J. Clin. Oncol.*, 22(22):4463-73 (2004).

KO, et al., "Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer", *J. Immunother.*, 27(3):232-9 (2004).

KOZAK, "Point mutations close to the AUG initiator codon affect the efficiency of translation of rat preproinsulin *in vivo*", *Nature*, 308(5956):241-6 (1984).

LADELL, et al., "A combination of plasmid DNAs encoding murine fetal liver kinase 1 extracellular domain, murine interleukin-12, and murine interferon-gamma inducible protein-10 leads to tumor regression and survival in melanoma-bearing mice", *J. Mol. Med.*, 81(4):271-8 (2003).

LEBERTHON, et al., "Enhanced tumor uptake of macromolecules induced by a novel vasoactive interleukin 2 immunoconjugate", *Cancer Res.*, 51(10):2694-8 (1991).

LI, et al., "Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy", *J. Natl. Cancer Inst.*, 94(10):762-8 (2002).

LI, et al. "Candidate genes associated with tumor regression mediated by intratumoral IL-12 electroporation gene therapy", *Mol. Ther.*, 9(3):347-54 (2004).

LIESCHKE, et al., "Bioactive murine and human interleukin-12 fusion proteins which retain antitumor activity *in vivo*", *Nat. Biotechnol.*, 15(1):35-40 (1997).

LINSLEY, et al., "CTLA-4 is a second receptor for the B cell activation antigen B7", *J. Exp. Med.*, 174(3):561-9 (1991).

LIU, et al., "Hormone conjugated with antibody to CD3 mediates cytotoxic T cell lysis of human melanoma cells", *Science*, 239(4838):395-8 (1988).

LO, et al., "High level expression and secretion of Fc-X fusion proteins in mammalian cells", *Protein Eng.*, 11(6):495-500 (1998).

LO, et al., "Engineering a pharmacologically superior form of leptin for the treatment of obesity", *Protein Eng. Des. Sel.*, 18(1):1-10 (2005).

LO, et al., "Targeted delivery of IL12 via a pan-tumor-specific antibody" (2005).

LO, et al., "huBC1-IL12, an immunocytokine which targets EDB-containing oncofetal fibronectin in tumors and tumor vasculature, shows potent anti-tumor activity in human tumor models", *Cancer Immunol. Immunother.*, 56(4):447-57 (2007).

LODE, et al., "Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow", *J. Natl. Cancer Inst.*, 89(21):1586-94 (1997).

LODE, et al., "Immunocytokines: a promising approach to cancer immunotherapy", *Pharmacol. Ther.*, 80(3):277-92 (1998).

LODE, et al., "Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy", *Blood*, 91(5):1706-15 (1998).

LODE, et al., "Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma", *Proc. Natl. Acad. Sci. U.S.A.*, 95(5):2475-80 (1998).

LODE, et al., "Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases", *Proc. Natl. Acad. Sci. U.S.A.*, 96(4):1591-6 (1999).

LODE, et al., "Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12", *Proc. Natl. Acad. Sci. U.S.A.*, 96(15):8591-6 (1999).

LODE, et al., "Amplification of T cell-mediated immune responses by antibody-cytokine fusion proteins", *Immunol. Invest.*, 29(2):117-20 (2000).

LODE, et al., "Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction", *J. Clin. Invest.*, 105(11):1623-30 (2000).

LODE, et al., "What to do with targeted IL-2", *Drugs Today (Barc)*, 36(5):321-36 (2000).

LOTZE, et al., "Cytokine gene therapy of cancer using interleukin-12: murine and clinical trials", *Ann. N.Y. Acad. Sci.*, 795:440-54 (1996).

MAGHAZACHI, et al., "Interferon-inducible protein-10 and lymphotactin induce the chemotaxis and mobilization of intracellular calcium in natural killer cells through pertussis toxin-sensitive and -insensitive heterotrimeric G-proteins", *FASEB J.*, 11(10):765-74 (1997).

MAJEWSKI, et al., "Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo", *J. Invest. Dermatol.*, 106(5):1114-8 (1996).

MANDPE, et al., "Cure of an established nonimmunogenic tumor, SCC VII, with a novel interleukin 12-based immunotherapy regimen in C3H mice", *Arch. Otolaryngol. Head Neck Surg.*, 129(7):786-92 (2003).

MARIANI, et al., "Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants", *Cancer*, 80(12 Suppl):2378-84 (1997).

MARK, et al., "Expression and characterization of hepatocyte growth factor receptor-IgG fusion proteins. Effects of mutations in the potential proteolytic cleavage site on processing and ligand binding", *J. Biol. Chem.*, 267(36):26166-71 (1992).

MARTINOTTI, et al., "CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes", *Eur. J. Immunol.*, 25(1):137-46 (1995).

MASIERO, et al., "New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12", *Angiogenesis*, 1(1):23-35 (1997).

MAZZOLINI, et al., "Regression of colon cancer and induction of antitumor immunity by intratumoral injection of adenovirus expressing interleukin-12", *Cancer Gene Ther.*, 6(6):514-22 (1999).

MEHROTRA, et al., "Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes", *J. Immunol.*, 151(5):2444-52 (1993).

MIDULLA, et al., "Source of oncofetal ED-B-containing fibronectin: implications of production by both tumor and endothelial cells", *Cancer Res.*, 60(1):164-9 (2000).

MORRISON, et al., "Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains", *Proc. Natl. Acad. Sci. U.S.A.*, 81(21):6851-5 (1984).

MOSMANN, et al., "TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties", *Annu. Rev. Immunol.*, 7:145-73 (1989).

MULLINS, et al., "Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation", *Immunopharmacol. Immunotoxicol.*, 20(4):473-92 (1998).

NARAMURA, et al., "Mechanisms of cellular cytotoxicity mediated by a recombinant antibody-IL2 fusion protein against human melanoma cells", *Immunol. Lett.*, 39(1):91-9 (1993).

NIETHAMMER, et al., "Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma", *Cancer Res.*, 61(16):6178-84 (2001).

O'SULLIVAN, et al., "Comparison of two methods of preparing enzyme-antibody conjugates: application of these conjugates for enzyme immunoassay", *Anal. Biochem.*, 100(1):100-8 (1979).

PALUCKA, et al., "Dendritic cells as the terminal stage of monocyte differentiation", *J. Immunol.*, 160(9):4587-95 (1998).

PANCOOK, et al., "Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2", *Cancer Immunol. Immunother.*, 42(2):88-92 (1996).

PARIHAR, et al., "IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells", *J. Clin. Invest.*, 110(7):983-92 (2002).

PARIHAR, et al., "A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients", *Clin. Cancer Res.*, 10(15):5027-37 (2004).

PARK, et al., "CD28 costimulation is required not only to induce IL-12 receptor but also to render janus kinases/STAT4 responsive to IL-12 stimulation in TCR-triggered T cells", *Eur. J. Immunol.*, 31(5):1456-64 (2001).

PEDLEY, et al., "Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent", *Cancer Res.*, 59(16):3998-4003 (1999).

PENG, et al., "Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3)", *J. Interferon Cytokine Res.*, 21(9):709-20 (2001).

PEREZ, et al., "Specific targeting of human peripheral blood T cells by heteroaggregates containing anti-T3 crosslinked to anti-target cell antibodies", *J. Exp. Med.*, 163(1):166-78 (1986).

PERUSSIA, et al., "Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-alpha beta+, TCR-gamma delta+ T lymphocytes, and NK cells", *J. Immunol.*, 149(11):3495-502 (1992).

PORTIELJE, et al., "Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant", *Cancer Immunol. Immunother.*, 54(1):37-43 (2005).

PUTZER, et al., "Interleukin 12 and B7-1 costimulatory molecule expressed by an adenovirus vector act synergistically to facilitate tumor regression", *Proc. Natl. Acad. Sci. U.S.A.*, 94(20):10889-94 (1997).

RAKHMILEVICH, et al., "Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody", *Mol. Cancer Ther.*, 3(8):969-76 (2004).

REISFELD, et al., "Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy", *J. Clin. Lab Anal.*, 10(3):160-6 (1996).

REISFELD, et al., "Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein", *Cancer Res.*, 56(8):1707-12 (1996).

REISFELD, et al., "Recombinant antibody fusion proteins for cancer immunotherapy", *Curr. Top. Microbiol. Immunol.*, 213 (Pt 3):27-53 (1996).

REISFELD, et al., "Immunocytokines: a new approach to immunotherapy of melanoma", *Melanoma Res.*, 7 Suppl 2:S99-106 (1997).

RIECHMANN, et al., "Reshaping human antibodies for therapy", *Nature*, 332(6162):323-7 (1988).

ROSENBERG, "Immunotherapy of cancer using interleukin 2: current status and future prospects", *Immunol. Today*, 9(2):58-62 (1988).

RUEHLMANN, et al. "MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma", *Cancer Res.*, 61(23):8498-503 (2001).

SABZEVARI, et al., "A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice", *Proc. Natl. Acad. Sci. U.S.A.*, 91(20):9626-30 (1994).

SAIKI, et al., "Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase", *Science*, 239(4839):487-91 (1988).

SAMBROOK, et al., Molecular Cloning, A Laboratory Manual, pp. 1.74-1.84 (1989).

SAVAGE, et al., "A recombinant single chain antibody interleukin-2 fusion protein", *Br. J. Cancer*, 67(2):304-10 (1993).

SCHNEE, et al, "Construction and expression of a recombinant antibody-targeted plasminogen activator", *Proc. Natl. Acad. Sci. U.S.A.*, 84(19):6904-8 (1987).

SCHOENHAUT, et al., "Cloning and expression of murine IL-12", *J. Immunol.*, 148(11):3433-40 (1992).

SETER, et al., "Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with etoposide phosphate", *Proc. Natl. Acad. Sci. U.S.A.*, 85(13):4842-6 (1988).

SHIN, et al., "Expression and characterization of an antibody binding specificity joined to insulin-like growth factor 1: potential applications for cellular targeting", *Proc. Natl. Acad. Sci. U.S.A.*, 87(14):5322-6 (1990).

SKERRA, et al., "Assembly of a functional immunoglobulin Fv fragment in *Escherichia coli*", *Science*, 240(4855):1038-41 (1988).

SOUTHERN, "Detection of specific sequences among DNA fragments separated by gel electrophoresis", *J. Mol. Biol.*, 98(3):503-17 (1975).

TAKAHARA, et al., "The ompA signal peptide directed secretion of Staphylococcal nuclease A by *Escherichia coli*", *J. Biol. Chem.*, 260(5):2670-4 (1985).

THORPE, et al., "The first international conference on vascular targeting: meeting overview", *Cancer Res.*, 63(5):1144-7 (2003).

TURNER, et al., "Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application", *J. Immunol. Methods*, 223(1):1-15 (1999).

TILL, et al., "An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins", *Cancer Res.*, 48(5):1119-23 (1988).

TILL, et al., "HIV-infected cells are killed by rCD4-ricin A chain", *Science*, 242(4882):1166-8 (1988).

TRINCHIERI, "Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes", *Blood*, 84(12):4008-27 (1994).

VAN HERPEN, et al., "Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor", *Clin. Cancer Res.*, 11(5):1899-909 (2005).

VAN VLIET, et al., "Distribution of fibronectin isoforms in human renal disease", *J. Pathol.*, 193(2):256-62 (2001).

VERHOEYEN, et al., "Reshaping human antibodies: grafting an antilysozyme activity", *Science*, 239(4847):1534-6 (1988).

VERMA, et al., "Targeted delivery of IL12 via an antibody for tumor and tmoral angiogenesis" (2006).

VITI, et al., "Increased binding affinity and valence of recombinant antibody fragments lead to improved targeting of tumoral angiogenesis", *Cancer Res.*, 59(2):347-52 (1999).

VOGEL, et al., "Direct binding of IL-12 to human and murine B lymphocytes", *Int. Immunol.*, 8(12):1955-62 (1996).

WADLER, et al., "A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96", *Gynecol. Oncol.*, 92(3):957-64 (2004).

WARD, et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from *Escherichia coli*", *Nature*, 341(6242):544-6 (1989).

WIGGINTON, et al., "Complete regression of established spontaneous mammary carcinoma and the therapeutic prevention of genetically programmed neoplastic transition by IL-12/pulse IL-2: induction of local T cell infiltration, Fas/Fas ligand gene expression, and mammary epithelial apoptosis", *J. Immunol.*, 166(2):1156-68 (2001).

WILLIAMS, et al., "Production of antibody-tagged enzymes by myeloma cells: application to DNA polymerase I Klenow fragment", *Gene*, 43(3):319-24 (1986).

WINTER and MILSTEIN, "Man-made antibodies", *Nature*, 349(6307):293-9 (1991).

WOOLEY, et al., "Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice", *J. Immunol.*, 151(11):6602-7 (1993).

XIANG, et al., "Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy", *Cancer Res.*, 57(21):4948-55 (1997).

YAMAZAKI, et al., "Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12", *Gene Ther.*, 9(1):64-74 (2002).

YOUNG, et al., "Thermal stabilization of a single-chain Fv antibody fragment by introduction of a disulphide bond", *FEBS Lett.*, 377(2):135-9 (1995).

ZAGOZDZON, et al., "Potentiation of antitumor effects of IL-12 in combination with paclitaxel in murine melanoma model *in vivo*", *Int. J. Mol. Med.*, 4(6):645-8 (1999).


ZHENG, et al., "Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation", *J. Immunol.*, 154(10):5590-600 (1995).

ZHU, et al., "Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor", *Invest. New Drugs*, 17(3):195-212 (1999).

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Charles Vorndran, Ph.D.
Reg. No. 45,315

Dated: October 24, 2007

PABST PATENT GROUP LLP
400 Colony Square, Suite 1200
1201 Peachtree Street
Atlanta, Georgia 30361
(404) 879-2153 (Telephone)
(404) 879-2160 (Fax)